Pensioenfonds Rail & OV acquired a new stake in shares of Stryker Corporation (NYSE:SYK – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,841 shares of the medical technology company’s stock, valued at approximately $5,739,000. Stryker accounts for about 1.5% of Pensioenfonds Rail & OV’s investment portfolio, making the stock its 24th biggest holding.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Gables Capital Management Inc. bought a new stake in Stryker in the 2nd quarter worth $25,000. Kilter Group LLC bought a new position in shares of Stryker during the second quarter valued at about $25,000. Cornerstone Financial Management LLC raised its stake in shares of Stryker by 66.0% during the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after acquiring an additional 31 shares during the last quarter. Highland Investment Advisors LLC purchased a new stake in shares of Stryker during the second quarter worth about $25,000. Finally, Compass Financial Management LLC purchased a new stake in shares of Stryker during the second quarter worth about $27,000. Institutional investors own 77.09% of the company’s stock.
Stryker Stock Down 1.1%
NYSE:SYK traded down $3.34 during trading hours on Friday, reaching $309.05. 3,251,740 shares of the company traded hands, compared to its average volume of 3,235,306. The business’s 50-day moving average price is $292.30 and its two-hundred day moving average price is $322.60. The stock has a market capitalization of $117.65 billion, a P/E ratio of 32.91, a P/E/G ratio of 2.14 and a beta of 0.78. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. During the same period last year, the company posted $3.19 earnings per share. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. Analysts predict that Stryker Corporation will post 14.85 earnings per share for the current year.
Insider Buying and Selling
In other news, Director Ronda E. Stryker sold 550,000 shares of the company’s stock in a transaction on Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the sale, the director directly owned 1,701,375 shares in the company, valued at $553,491,315. This represents a 24.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 901,267 shares of company stock valued at $297,123,701 over the last 90 days. Company insiders own 4.60% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on SYK. Deutsche Bank reduced their price target on Stryker from $315.00 to $275.00 and set a “hold” rating on the stock in a report on Friday, October 30th. Canaccord Genuity Group cut Stryker from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $385.00 to $300.00 in a report on Friday, October 30th. Stifel Nicolaus cut their price objective on Stryker from $330.00 to $325.00 and set a “buy” rating on the stock in a research report on Monday, November 2nd. BMO Capital Markets reissued an “outperform” rating and set a $309.00 target price (down from $317.00) on shares of Stryker in a research note on Friday, October 30th. Finally, Truist Financial restated a “hold” rating and set a $305.00 target price (down from $310.00) on shares of Stryker in a report on Monday, November 2nd. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $342.19.
Get Our Latest Analysis on Stryker
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Recommended Stories
- Five stocks we like better than Stryker
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
